IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in glioma cells in vitro and in vivo

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 427-432

  Wang, Ju Bo ^a   Dong, Dan Feng ^a   Wang, Mao De ^a   Gao, Ke ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Chemotherapy; Glioma; Invasion; Isocitrate dehydrogenase 1; Proliferation

Indexed keywords

ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; TEMOZOLOMIDE;

ANIMAL; APOPTOSIS; ARTICLE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETICS; GLIOMA; HUMAN; MALE; METABOLISM; MOUSE; MUTATION; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MICE; MICE, NUDE; MUTATION;

EID: 84894062541     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.427     Document Type: Article

References (26)

1. Babu R, Sharma R, Karikari IO, et al (2012). Outcome and prognostic factors in adult cerebelar glioblastoma. J Clin Neurosci, 20, 1117-21.
2. Baldewpersad Tewarie NM, Burgers IA, Dawood Y, et al (2013). NADP (+)-dependent IDH (R132) mutation and its relevance for glioma patient survival. Med Hypothesis, 80, 728-31.
3. Buonerba C, Di Lorenzo G, Marinelli A, et al (2011). A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol, 80, 54-68.
4. CBTRUS (2009-2010). Central Brain Tumor Registry of the US Statistical Report. Published by the Central Brain Tumor Registry of the United States.
5. Chen Rx, Cui JF, Xu CD, et al (2012). The signifificance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol, 19, S375-84.
6. Chen YN, Chen JC, Yin SC, et al (2002). Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer, 100, 158-65.
7. Combs SE, Gutwein S, Ertner DS, et al (2005). Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme: Phase I/II study. Strahlenther Onkol, 181, 372-7.
8. Dai CX, Zhang B, Liu XH, et al (2013). Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways. Int J Cancer, 133, 1982-93.
9. Dang L, White DW, Gross S, et al (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462, 739-U52.
10. Irena R, Jasminka JR, Velibor P, et al (2012). Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol, 29, 561-9.
11. Jansen MPHM, Reijm EA, Sieuwerts AM, et al (2012). High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res TR, 133, 937-47.
12. Langers AMJ, Verspaget HW, Hawinkels LJAC, et al (2012). MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer, 106, 1495-8.
13. Lewandowska MA, Furtak J, Szylberg T, et al (2013). An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in polish glioma patients. Mol Diagn Ther, 2, 785-96.
14. Li RY, Chen LC, Zhang HY, et al (2013). MiR-139 inhibits Mcl-1 expression and potentiates TMZ-Induced apoptosis in glioma. CNS Neurosci Ther, 19, 477-83.
15. Nobusawa S, Watanabe T, Kleihues P, et al (2009). IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res, 15, 6002-7.
16. Parsons DW, Jones S, Zhang X et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12.
17. Quaranta M, Daniele A, Coviello M, et al (2007). MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res, 27, 3593-600.
18. Que XY, Li Y, Han Y, et al (2013). Effects of siRNA-mediated CDC2 silencing on MG63 cell proliferation and apoptosis. Mol Med Rep, 7, 466-70.
19. Sherman JH, Hoes K, Marcus J, et al (2011). Neurosurgery for brain tumors: update on recent technical advances. Curr Neurol Neurosci Rep, 11, 313-9.
20. Stupp R, Mason WP, van den Bent MJ, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med, 352, 987-96.
21. Timme CR, Gruidl M, Yeatman TJ (2013). Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xl in human colon cancer cells. Apoptosis, 18, 1163-74.
22. Turcan S, Rohle D, Goenka A, et al (2012). IDH1 mutation is suffificient to establish the glioma hypermethylator phenotype. Nature, 483, 470-U137.
23. Wen PY, Kesari S (2008). Malignant gliomas in adults. N Engl J Med, 359, 492-507.
24. Yan H, Parsons DW, Jin G, et al (2009). Idh1 and Idh2 mutations in gliomas. N Engl J Med, 360, 765-73.
25. Yang T, Zhang YL, Li YL (2013). High amounts of fluoride induce apoptosis/cell death in matured ameloblast-like LS8 cells by down regulating Bcl-2. Arch Oral Biol, 58, 1165-73.
26. Yu CJ, Wang ZC, Wang ZY, et al (2008). Incidence of intracranial tumors. In 'Neurosurgery'. Chief Ed: Wang ZC. Hubei, Science and Technology Press, 512-8.